Stock KALV KALVISTA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus KalVista Pharmaceuticals, Inc.

Equities

KALV

US4834971032

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-20 pm EDT 		5-day change 1st Jan Change
11.88 USD -0.34% Intraday chart for KalVista Pharmaceuticals, Inc. -1.00% -3.02%
Apr. 22 Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors CI
Apr. 15 Certain Common Stock of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024. CI

Evolution of the average Target Price on KalVista Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

a7939fdcf5828f9b1bc.ciPQRpTzSuoOfDSpeHuEhM-0YgCscVff5VMH_0G6Oko.PEmhNfOeLIdnC0WEIB218Y2CKnfBCzuAqz9uvAvRfHocVbg8xZEpg1szAA~3e1b802729d8e5faa5e4445674765c61

Analyst Recommendations on KalVista Pharmaceuticals, Inc.

HC Wainwright Adjusts Price Target on KalVista Pharmaceuticals to $24 From $16, Maintains Buy Rating MT
SVB Securities Adjusts KalVista Pharmaceuticals' Price Target to $20 From $30, Maintains Outperform Rating MT
HC Wainwright Adjusts KalVista Pharmaceuticals' Price Target to $16 From $48, Reiterates Buy Rating MT
SVB Securities Adjusts Price Target on KalVista Pharmaceuticals to $30 From $45, Keeps Outperform Rating MT
Needham Lowers KalVista Pharmaceuticals Price Target to $24 From $38, Maintains Buy Rating MT
SVB Securities Adjusts KalVista Pharmaceuticals' Price Target to $45 from $51, Keeps Outperform Rating MT
Needham Adjusts Price Target on KalVista Pharmaceuticals to $38 From $42, Reiterates Buy Rating MT
Stifel Nicolaus Adjusts KalVista Pharmaceuticals' Price Target to $32 From $54, Maintains Buy Rating MT
Needham Adjusts KalVista Pharmaceuticals' Price Target to $42 from $48, Keeps Buy Rating MT
Cantor Fitzgerald Lowers Price Target for KalVista Pharmaceuticals to $33 From $49, Maintains Overweight Rating MT
Needham Adjusts KalVista Pharmaceuticals' Price Target to $48 from $50, Keeps Buy Rating MT
KALVISTA PHARMACEUTICALS : Roth Capital Adjusts Price Target on KalVista Pharmaceuticals to $55 From $30, Maintains Buy Rating MT
KALVISTA PHARMACEUTICALS : SVB Leerink Adjusts Price Target on KalVista Pharmaceuticals to $51 From $39, Keeps Outperform Rating MT
KALVISTA PHARMACEUTICALS : HC Wainwright Adjusts Price Target on KalVista Pharmaceuticals to $48 From $30, Maintains Buy Rating MT
KALVISTA PHARMACEUTICALS : Stifel Adjusts Price Target on KalVista Pharmaceuticals to $54 From $30, Reiterates Buy Rating MT
KALVISTA PHARMACEUTICALS : Needham Adjusts KalVista Pharmaceuticals' Price Target to $32 From $25, Keeps at Buy MT
KALVISTA PHARMACEUTICALS : SVB Leerink Adjusts KalVista Pharmaceuticals' Price Target to $39 From $28, Keeps at Outperform MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
11.88 USD
Average target price
29.8 USD
Spread / Average Target
+150.84%
High Price Target
39 USD
Spread / Highest target
+228.28%
Low Price Target
20 USD
Spread / Lowest Target
+68.35%

Consensus detail

Consensus revision (last 18 months)

Analysts covering KalVista Pharmaceuticals, Inc.

HC Wainwright
SVB Securities LLC
Needham & Co.
Stifel Nicolaus
Cantor Fitzgerald
Roth Capital Partners
SVB Leerink

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. KALV Stock
  4. Consensus KalVista Pharmaceuticals, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW